Imaging
the widely-published IRDye® 800CW dye and IRDye 680RD, a new dye specifically designed for small animal imaging. Ready-to-use BrightSite™ optical agents with IRDye labels target a variety of disease characteristics, so you can start your experi- ments immediately without developing and charac- terising new agents. Targets include overexpression of cell surface proteins such as EGFR and −inte- grins, glucose metabolism, bone mineralisation, vas- culature changes in tumours, and lymphatic track- ing. IRDye reactive dyes and labelling kits can be used to develop probes for custom targets. LI-COR Biosciences’ growing portfolio of in vivo imaging reagents now includes IRDye 680RD optical agents, labelling kits, and reactive dyes suitable for single- target or multi-target imaging.
Figure 16: In vitro neuronal progenitors cells labelled intracellularly with Viscover FeraTrack (anti-dextran immunofluorescence) reagents from Miltenyi Biotec
and provides strong potential for clinical transla- tion. The Pearl® Impulse Imaging System combines high-performance NIR imaging with easy-to-use image capture and analysis tools that make it easy for new users to get started. Near-infrared laser exci- tation (685 and 785nm) and FieldBrite™ technolo- gy enable an unprecedented 6-log dynamic range and simultaneous multi-target imaging (Figure 15). Pearl Impulse is optimised for NIR dyes, including
Viscover™ from Miltenyi Biotec (
www.milteny-
ibiotec.com) represents the first integrated range of in vivo contrast agents for preclinical imaging in small animals using the modalities MRI, CT, opti- cal imaging and ultrasound. Its tools include novel molecules and pharmacologies, as well as the appli- cation of trusted standards in clinical practice for animal imaging. Viscover developers are committed to animal welfare and the ‘3 Rs’ of animal research: Replace, Reduce, Refine. As replacement is not always feasible, Viscover agents have been opti- mised to reduce the numbers of animals per study and to refine image technology to yield superior images while reducing time and costs. Its sterile, low viscosity pre-formulation gives you unrivalled convenience and an excellent safety profile in many different species. Contrast enhancement lasts for several hours and because the safety pharmacology of each formulation has been optimised repeat dos- ing is always an option for the pre-clinical investi- gator. The new FeraTrack™ superparamagnetic iron oxide contrast agent simplifies intracellular labeling of cells ex vivo using a convenient two- component kit. Once labelled with FeraTrack, cells can be tracked in recipient animals using MRI. Intracellular labelling of neural progenitor cells and their injection into the mouse cortex resulted in a group of labelled cells in the left cortex that were clearly identifiable by MRI (Figure 16).
Figure 17: PerkinElmer’s FMT 2500 LX system and the accessories that are typically used with the instrument
66
PerkinElmer (
www.perkinelmer.com) moved into the preclinical imaging market with the acquisition of VisEn Medical in August 2010. This acquisition extended the portfolio of imaging solutions that now extends from confocal microscopy for sub- cellular image analysis to whole animal imaging in vivo. The product solution offered is based on Fluorescence Molecular Tomography (FMT®)
Drug Discovery World Summer 2011
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92